Supplement analysis backed by scientific evidence · PT

← All supplements
Limited evidenceLongevity & antioxidants

Cycloastragenol

The astragalus compound behind commercial telomerase activators. One small randomized trial found changes in cardiovascular markers, but no human study has convincingly shown telomere lengthening or any anti-ageing outcome.

Evidence last reviewed: August 2026

What the science says

  • Telomerase activation and telomere length Limited evidence

    The telomerase-activating effect is documented in cell culture; in animals, a randomized study of the branded TA-65 product in bird chicks found no increase in telomere length during development. Human telomere data come mostly from uncontrolled or industry-linked observations.

  • Cardiovascular markers Limited evidence

    A randomized controlled trial of TA-65 in patients with metabolic syndrome reported improvements in some cardiovascular markers such as HDL and glucose. It was a single small trial with surrogate endpoints and industry involvement.

  • Anti-ageing effects on skin and bone Limited evidence

    A 2026 review of Astragalus membranaceus summarizes potential anti-ageing and anticancer activity on skin and bone, based on preclinical work. No clinical trial supports these uses.

Dosage & safety

Studied doseThe metabolic syndrome trial used 16 mg/day of the branded TA-65 preparation. Generic cycloastragenol products list 5–25 mg/day, with variable and often unverified purity.
SafetyShort-term trials reported no serious adverse effects. The theoretical concern with any telomerase activator is that it could support survival of pre-malignant cells; this has not been demonstrated but has not been excluded either. Avoid with a history of cancer, in pregnancy, breastfeeding, and alongside immunosuppressants, since astragalus is immunostimulating.

Scientific references

Where to buy

View on iHerb

Referral link — this site may earn a commission on purchases.

Related in Longevity & antioxidants